Optimized Protocol for Quantitative Multiple Reaction Monitoring-Based Proteomic Analysis of Formalin-Fixed, Paraffin-Embedded Tissues
Overview
Authors
Affiliations
Despite a clinical, economic, and regulatory imperative to develop companion diagnostics, precious few new biomarkers have been successfully translated into clinical use, due in part to inadequate protein assay technologies to support large-scale testing of hundreds of candidate biomarkers in formalin-fixed paraffin-embedded (FFPE) tissues. Although the feasibility of using targeted, multiple reaction monitoring mass spectrometry (MRM-MS) for quantitative analyses of FFPE tissues has been demonstrated, protocols have not been systematically optimized for robust quantification across a large number of analytes, nor has the performance of peptide immuno-MRM been evaluated. To address this gap, we used a test battery approach coupled to MRM-MS with the addition of stable isotope-labeled standard peptides (targeting 512 analytes) to quantitatively evaluate the performance of three extraction protocols in combination with three trypsin digestion protocols (i.e., nine processes). A process based on RapiGest buffer extraction and urea-based digestion was identified to enable similar quantitation results from FFPE and frozen tissues. Using the optimized protocols for MRM-based analysis of FFPE tissues, median precision was 11.4% (across 249 analytes). There was excellent correlation between measurements made on matched FFPE and frozen tissues, both for direct MRM analysis (R(2) = 0.94) and immuno-MRM (R(2) = 0.89). The optimized process enables highly reproducible, multiplex, standardizable, quantitative MRM in archival tissue specimens.
Investigating proteogenomic divergence in patient-derived xenograft models of ovarian cancer.
Perez J, Duda J, Ryu J, Shetty M, Mehta S, Jagtap P Sci Rep. 2025; 15(1):813.
PMID: 39755759 PMC: 11700199. DOI: 10.1038/s41598-024-84874-3.
Darville L, Lockhart J, Reddy S, Fang B, Izumi V, Boyle T Methods Mol Biol. 2024; 2823:193-223.
PMID: 39052222 PMC: 11648944. DOI: 10.1007/978-1-0716-3922-1_13.
Pan-cancer proteogenomics characterization of tumor immunity.
Petralia F, Ma W, Yaron T, Caruso F, Tignor N, Wang J Cell. 2024; 187(5):1255-1277.e27.
PMID: 38359819 PMC: 10988632. DOI: 10.1016/j.cell.2024.01.027.
Clinical Proteomics for Solid Organ Tissues.
Phipps W, Kilgore M, Kennedy J, Whiteaker J, Hoofnagle A, Paulovich A Mol Cell Proteomics. 2023; 22(11):100648.
PMID: 37730181 PMC: 10692389. DOI: 10.1016/j.mcpro.2023.100648.
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
Chowdhury S, Kennedy J, Ivey R, Murillo O, Hosseini N, Song X Cell. 2023; 186(16):3476-3498.e35.
PMID: 37541199 PMC: 10414761. DOI: 10.1016/j.cell.2023.07.004.